JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, I.
Right arrow Articles by Lipkin, W. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, I.
Right arrow Articles by Lipkin, W. I.

 Previous Article  |  Next Article 

Journal of Virology, September 1999, p. 7903-7906, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Inhibition of Borna Disease Virus Replication by Ribavirin

Ingo Jordan,1 Thomas Briese,1 Devron R. Averett,2 and W. Ian Lipkin1,*

Laboratory for the Study of Emerging Diseases, Department of Neurology, University of California, Irvine, California 92697-4292,1 and ICN Pharmaceuticals, Inc., Costa Mesa, California 926262

Received 12 February 1999/Accepted 14 June 1999

The guanosine analogue ribavirin was tested for antiviral activity in two neural cell lines, human oligodendrocytes and rat glia, against Borna disease virus (BDV) strains V and He/80. Ribavirin treatment resulted in lower levels of virus and viral transcripts within 12 h. Addition of guanosine but not adenosine resulted in a profound reduction of the ribavirin effect. Ribavirin appears to be an effective antiviral agent for treatment of BDV infection in vitro. A likely mechanism for its activity is reduction of the intracellular GTP pool, resulting in inhibition of transcription and capping of BDV mRNAs.

* Corresponding author. Mailing address: Laboratory for the Study of Emerging Diseases, Department of Neurology, University of California, Irvine, CA 92697-4292. Phone: (949) 824-6193. Fax: (949) 824-1229. E-mail: ilipkin{at}uci.edu.

Journal of Virology, September 1999, p. 7903-7906, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.